 | Up a level |
Benzarti, Sonia; Daskalakis, Michael; Feller, Anita; Bacher, Vera Ulrike; Schnegg-Kaufmann, Annatina; Rüfer, Axel; Holbro, Andreas; Schmidt, Adrian; Benz, Rudolf; Solenthaler, Max; Stussi, Georg; Arndt, Volker; Bonadies, Nicolas (2019). Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. Cancer epidemiology, 59, pp. 51-57. Elsevier 10.1016/j.canep.2019.01.003
Junge, Alexandra; Bacher, Vera Ulrike; Mueller, Beatrice U; Keller, Peter; Solenthaler, Max; Pabst Müller, Thomas Niklaus (2018). Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. (In Press). Hematological oncology Wiley 10.1002/hon.2516
Colucci, Giuseppe; Silzle, Tobias; Solenthaler, Max (2012). Pyrazinamide-induced sideroblastic anemia. American journal of hematology, 87(3), p. 305. New York, N.Y.: Wiley-Liss 10.1002/ajh.2830280316
Leupin, Nicolas; Schuller, Jan C; Solenthaler, Max; Heim, Dominik; Rovo, Alicia; Beretta, Kurt; Gregor, Michael; Bargetzi, Mario J; Brauchli, Peter; Himmelmann, Andreas; Hanselmann, Silvia; Zenhäusern, Reinhard (2010). Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leukemia & lymphoma, 51(4), pp. 613-9. London: Informa Healthcare 10.3109/10428191003624231
Heimpel, Hermann; Dührsen, Ulrich; Hofbauer, P; Rigamonti-Wermlinger, V; Kreuser, Ernst-Dietrich; Schwarz, Klaus; Solenthaler, Max; Pauls, S (2009). Bulky extramedullary hematopoiesis is not a rare complication of congenital dyserythropoietic anemia. Annals of hematology, 88(10), pp. 937-41. Berlin: Springer 10.1007/s00277-009-0735-5
Zenhäusern, Reinhard; Von Rohr, Albert; Rufibach, Kaspar; Solenthaler, Max; Meyer-Monard, Sandrine; Gratwohl, Alois; Hess, Urs; Bargetzi, Mario J; Kovacsovic, Tibor; Leoncini, Leda; Tobler, Andreas (2009). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Leukemia & lymphoma, 50(1), pp. 133-6. London: Informa Healthcare 10.1080/10428190802527681
Mumprecht, Sabine Barbara; Schürch, Christian; Schwaller, Juerg; Solenthaler, Max; Ochsenbein, Adrian F (2009). Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114(8), pp. 1528-1536. Washington, D.C.: American Society of Hematology 10.1182/blood-2008-09-179697
Hehlmann, Rüdiger; Berger, Ute; Pfirrmann, Markus; Heimpel, Hermann; Hochhaus, Andreas; Hasford, Joerg; Kolb, Hans-Jochem; Lahaye, Tanja; Maywald, Ole; Reiter, Andreas; Hossfeld, Dieter K; Huber, Christoph; Löffler, Helmut; Pralle, Hans; Queisser, Wolfgang; Tobler, Andreas; Nerl, Christoph; Solenthaler, Max; Goebeler, Mariele E; Griesshammer, Martin; ... (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 109(11), pp. 4686-92. Washington, D.C.: American Society of Hematology 10.1182/blood-2006-11-055186
